Autor: |
Ramanan AV; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK avramanan@hotmail.com.; Translational Health Sciences, University of Bristol, Bristol, UK., Wason JMS; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK. |
Jazyk: |
angličtina |
Zdroj: |
Archives of disease in childhood [Arch Dis Child] 2024 Jun 11. Date of Electronic Publication: 2024 Jun 11. |
DOI: |
10.1136/archdischild-2024-327143 |
Abstrakt: |
Competing Interests: Competing interests: JW—none relevant to the manuscript but funding to institution from AstraZeneca, Boehringer-Ingelheim, Hemay, Mirobio, Nemeysis, Novartis, Orbsen, UCB and Worg. AVR—none relevant to the manuscript; speaker fees/honoraria/consultancy from AbbVie, Eli Lilly, UCB, SOBI, Novartis, AstraZeneca and Roche. |
Databáze: |
MEDLINE |
Externí odkaz: |
|